CLINICAL STUDY PROTOCOL  
 
A Sibling Oocyte Study - Comparison of 
ZyMotTM Microfluidics Device to Density 
Gradient for Sperm Selection During ICSI  
 
Principal Investigator  
[INVESTIGATOR_309439]  
[ADDRESS_379382], Gaithersburg, MD, [ZIP_CODE] -3429, [LOCATION_002]  
https://zymotfertility.com/  
 
Protocol Version  
17 March  2021  
version DRAFT  
 
  
Study: i21 -[ZIP_CODE]  
Page 2 of 25 
Study Personnel  
Principal Investigator  [INVESTIGATOR_309440]: [EMAIL_6091]  
  
Sub-Investigator s Alicia Arnott  
Email: [EMAIL_6092]  
  
  Meredith Akerman  
Email: [EMAIL_6093]  
  
  Linda  Sung  
Email: [EMAIL_6094]  
  
  Maria  Saketos  
Email: [EMAIL_6095]  
  
  Satu Kuokkanen  
Email: [EMAIL_6096]  
  
  Vasilios Goudas  
Email: [EMAIL_6097]  
  Jessica Tozour  
Email: [EMAIL_6098]  
  
  Daniela  Schab  
Email: [EMAIL_6099]  
  
  Catherine  Dennis  
Email: [EMAIL_6100]  
  
Key Study Personnel:  Alicia Arnott  
Email: [EMAIL_6092]  
  
  Meredith Akerman  
Email: [EMAIL_6093]  
  
 
  
Study: i21 -[ZIP_CODE]  
Page 3 of 25 
Synopsis  
 
Primary Objective  
The primary objective of this study is to evaluate whether the percentage of good quality 
embryo formation following ICSI is improved with the use of ZyMot method of microfluidic 
sperm separation compared to density gradient.  
 
Secondary Objectives  
The secondary objectives will be to evaluate:  
1. Sperm parameters prior to and following sperm separation with ZyMot compared to 
density gradient  
2. Normal fertilization rates following ICSI comparing sperm separation with ZyMot with 
density gradient  
3. Euploid rates, in the event that PGT -A was performed, fol lowing ICSI comparing 
sperm separation with ZyMot with density gradient  
4. Embryo transfer results including:  
5. Not pregnant  
6. Biochemical pregnancy, defined as BHCG value > 5 mIU/ml without ultrasound 
evidence of gestational sac within the uterus  
7. Clinical miscarriage, defined as loss of a pregnancy following a positive BHCG value 
and ultrasound revealing presence of a gestational sac within the uterus  
8. Clinical pregnancy, defined as positive BHCG with a gestational sac within the uterus  
9. Ongoing Preg nancy, defined as a positive BHCG value with ultrasound evidence of 
intrauterine gestational sac at or past [ADDRESS_379383] protocol. 
On the day of oocyte retrieval, sperm samples will be split into two samples and processed 
via density gradient (our standard sperm separation technique) a nd ZyMot (our experimental 
arm). Sperm parameters will be evaluated pre and post -sperm separation following ZyMot 
and density gradient. Following oocyte retrieval, the oocytes will be assessed as per our 
standard fashion. In the event that the oocytes will  be inseminated via intracytoplasmic 
sperm injection (ICSI) and there are 6 or more mature oocytes, half of the oocytes will be 
inseminated via ZyMot processed sperm and half with sperm processed via density gradient. 
In the event that there are less than 6 mature oocytes or the insemination technique will be 
IVF, the oocytes will only be inseminated with sperm processed via density gradient. 
Additionally, in the event that the sperm sample is insufficient for ZyMot processing (<0.5 
million total motile spe rm and/or no sperm observed with progressive forward motility), the 
sperm will not be processed with ZyMot and the patient will be withdrawn from the study.  
 
The primary outcome will be percentage of good quality embryo formation resulting from 
oocytes in seminated following ZyMot separated sperm compared to density gradient 
separated sperm. Secondary outcomes will include percentage of euploid embryos in the 
Study: i21 -[ADDRESS_379384] protocols regardless of the sperm processing technique.  
 
Study Population  
The study population will include patient/ sperm donor dyads where all patients o ver [ADDRESS_379385] 6 mature oocytes retrieved.  The sperm source/ donor will provide 
informed consent for the use of their sperm sample in this re search study . The relationship 
of the sperm source will can be the intended father, a known sperm donor  in a same -sex 
couple or a known donor in the case of a single patient. The identity of the donor cannot be 
anonymous.   
 
Number of Participants  
Following power calculation, 408 oocytes will be needed to randomize (see details in the 
statistics section). The number of patient/sperm source dyads enrolled will depend on the 
number of oocytes obtained from each patient. The maximum number of subjects will be 68 
(in the event that 6 oocytes were obtained from every patient enrolled in the study).  
Number of Study Sites  
This study will take place at NYU Langone Reproductive Specialists of NY.  
 
Primary Outcome Variables  
The primary outcome of our study  is to evaluate whether good quality embryo formation is 
significantly improved with ICSI following sperm separation using ZyMot compared to 
density gradient.  
 
Secondary and Exploratory Outcome Variables  
The secondary objectives will be to evaluate:  
1. Sperm parameters prior to and following sperm separation with ZyMot compared to 
density gradient  
2. Normal fertilization rates following ICSI comparing sperm separation with ZyMot with 
density gradient  
3. Euploid rates, in the event that PGT -A was performed, following ICSI comparing 
sperm separation with ZyMot with density gradient  
4. Embryo transfer results including:  
a. Not pregnant  
b. Biochemical pregnancy, defined as BHCG value > 5 mIU/ml without 
ultrasound evidence of gestational sac within the uterus  
c. Clinical miscarriage, defined as loss of a pregnancy following a positive 
BHCG value and ultrasound revealing presence of a gestational sac within 
the uterus  
d. Clinical pregnancy, defined as positive BHCG with a gestational sac within 
the uterus  
e. Ongoing Pregn ancy, defined as a positive BHCG value with ultrasound 
evidence of intrauterine gestational sac at or past [ADDRESS_379386], 
or definite movement of the voluntary muscles.  
g. Ectopic Pregnancy, defined as positive BHCG and presence of pregnancy 
outside of the uterus.  
 
 
 
Study: i21 -[ZIP_CODE]  
Page 5 of 25 
Abbreviations  
Abbreviation  Explanation  
ART Assisted reproductive technologies  
DNA  Deoxyribonucleic acid  
ICSI Intracytoplasmic sperm injection  
IVF In vitro fertilization  
PGT Preimplantation genetic testing  
PGT-A Preimplantation genetic testing for aneuploidy  
PI [INVESTIGATOR_309441]: i21 -[ZIP_CODE]  
Page 6 of 25 
Table of Contents  
Synopsis  ................................ ................................ ................................ ................................ ......3 
Primary Objective  ................................ ................................ ................................ ................... 3 
Secondary Objectives (if applicable)  ................................ ................................ ...................... 3 
Study Duration  ................................ ................................ ................................ ........................ 3 
Study Design  ................................ ................................ ................................ .......................... 3 
Study Population  ................................ ................................ ................................ .................... 4 
Number of Participants  ................................ ................................ ................................ ........... 4 
Number of Study Sites ................................ ................................ ................................ ............. 4 
Primary Outcome Variables  ................................ ................................ ................................ ...4 
Secondary and Exploratory Outcome Variables (if applicable)  ................................ ............. 4 
Visit Sc hedule Table (Optional)  ................................ ................................ ................................ . 
Study Flow Chart (optional)  ................................ ................................ ................................ ....... 
Abbreviations  ................................ ................................ ................................ .............................. 5 
Glossary of Terms  ................................ ................................ ................................ .........................  
1 - Introduc tion ................................ ................................ ................................ ............................ 8 
1.1 Introductory Statement  ................................ ................................ ................................ .....8 
2 - Background  ................................ ................................ ................................ ............................ 8 
2.1 Background/prevalence of research topic  ................................ ................................ .......8 
2.2.1 Device Preclinical Experience  ................................ ................................ ................... 9 
2.2.2 Device Clinical Experience  ................................ ................................ .....................  10 
3 - Rationale/Significance  ................................ ................................ ................................ ........  10 
3.1 Problem Statement  ................................ ................................ ................................ ........  10 
3.2 Purpose of Study/Potential Impact  ................................ ................................ ................  10 
3.3.1 Potential Risks  ................................ ................................ ................................ .........  10 
3.3.2 Potential Benefits  ................................ ................................ ................................ .... 11 
4 - Study Objectives  ................................ ................................ ................................ .................  11 
4.1 Hypothesis  ................................ ................................ ................................ ......................  11 
4.2 Primary Objective  ................................ ................................ ................................ ..........  11 
4.3 Secondary Objectives (if applicable) ................................ ................................ .............  11 
5 - Study Design  ................................ ................................ ................................ ......................  11 
5.1 General Design Description  ................................ ................................ ..........................  11 
5.1.1 Study Date Range and Duration  ................................ ................................ ..............  12 
5.1.2 Number of Study Sites  ................................ ................................ .............................  12 
5.2 Outcome Variables  ................................ ................................ ................................ .........  12 
5.2.1 Primary Outcom e Variables  ................................ ................................ ....................  12 
5.2.2 Secondary and Exploratory Outcome Variables (if applicable)  .............................  12 
5.3 Study Population  ................................ ................................ ................................ ...........  12 
5.3.1 Number of Participants  ................................ ................................ ...........................  13 
5.3.2 Eligibility Criteria/Vulnerable Populations  ................................ ...............................  13 
6 - Methods  ................................ ................................ ................................ ..............................  13 
6.1 Treatment - Device  ................................ ................................ ................................ .........  13 
6.1.1 Intended use for the device  ................................ ................................ .....................  14 
6.1.2 Device administration and sc hedule  ................................ ................................ ....... 14 
6.1.3 Method of Assignment/Randomization  ................................ ................................ ... 15 
6.1.4 Device Calibration  ................................ ................................ ................................ ... 16 
6.1.5 Storage Condition  ................................ ................................ ................................ ... 16 
6.1.6 Concomittant therapy  ................................ ................................ ...............................  16 
6.1.7 Restrictions ................................ ................................ ................................ ..............  16 
6.2 Assessments  ................................ ................................ ................................ ..................  16 
6.2.1 Efficacy  ................................ ................................ ................................ ....................  16 
6.2.2 Safety/Pregnancy -related policy  ................................ ................................ ..............  16 
[IP_ADDRESS] Adverse Events Definition and Reporting  ................................ ............................  16 
6.2.3 Pharmaco kinetics (if applicable)  ................................ ................................ ...................  
Study: i21 -[ZIP_CODE]  
Page 7 of 25 
6.2.4 Biomarkers (if applicable)  ................................ ................................ .............................  
6.3 Study Procedures  ................................ ................................ ................................ ...............  
6.3.1 Study Schedule  ................................ ................................ ................................ ....... 19 
6.3.2 Informed Consent ................................ ................................ ................................ .... 20 
6.3.3 Screening  ................................ ................................ ................................ .................  20 
6.3.4 Recruitment, Enrollment and Retention ................................ ................................ .. 20 
6.3.5 On Study Visits  ................................ ................................ ................................ .........  21 
6.3.6 End of Study and Follow -up ................................ ................................ .....................  21 
6.3.7 Removal of subjects  ................................ ................................ ................................  21 
6.4 Statistical Method  ................................ ................................ ................................ ...........  21 
6.4.1 Statistical Design ................................ ................................ ................................ ..... 21 
6.4.2 Sample Size Considerations  ................................ ................................ ...................  21 
6.4.3 Planned Analyses  ................................ ................................ ................................ ........  22 
[IP_ADDRESS] Primary Analyses  ................................ ................................ ................................ . 22 
[IP_ADDRESS] Secondary Objectives Analyses  ................................ ................................ ..........  22 
[IP_ADDRESS] Safety/Pregnancy -related policy  ................................ ................................ ...........  22 
[IP_ADDRESS] Analysis of Subject Characteristics  ................................ ................................ ...... 22 
[IP_ADDRESS] Interim Analysis (if applicable)  ................................ ................................ .............  22 
[IP_ADDRESS] Health economic evaluation  ................................ ................................ ..................  22 
[IP_ADDRESS] Other  ................................ ................................ ................................ .....................  22 
6.4.4 Subsets and Covariates  ................................ ................................ ..........................  22 
6.4.5 Handling of Missing Data  ................................ ................................ ........................  22 
7 - Trial Administration  ................................ ................................ ................................ .............  23 
7.1 Ethical Considerations: In formed Consent/Assent and HIPAA Authorization  ..............  [ADDRESS_379387] (IRB) Review  ................................ ................................ ...... [ADDRESS_379388] Confidentiality  ................................ ................................ ................................ ... 23 
7.4 Deviations/Unanticipated Problems  ................................ ................................ ..............  23 
7.5 Data Collection  ................................ ................................ ................................ ..............  23 
7.6 Data Quality Assurance ................................ ................................ ................................ .. 24 
7.7 Study Records  ................................ ................................ ................................ ................  24 
7.8 Access to Source ................................ ................................ ................................ ...........  24 
7.9 Data or Specimen Storage/Security  ................................ ................................ ..............  [ADDRESS_379389] of Tables  ................................ ................................ ................................ ................................ . 
References  ................................ ................................ ................................ ................................ .... 
 
  
Study: i21 -[ZIP_CODE]  
Page 8 of 25 
1 - Introduction  
1.1 Introductory Statement  
The primary objective of this study is to evaluate whether the percentage of good quality embryo 
formation following ICSI is improved with the use of ZyMot method of microfluidic sperm separation 
compared to density gradient.  
 
2 - Background  
2.1 Background/prevalence of research topic  
Sperm integrity and function is critical to embryo formation and IVF success rates. Male factor 
infertility accounts  for approximately 1/[ADDRESS_379390] common 
diagnosis for IVF cycles in the US. During an IVF cycle, oocytes retrieved are inseminated with sperm 
via IVF or ICSI. IVF is the process by [CONTACT_309450] 50,000 -100,000 mo tile sperm are 
incubated with one or more oocytes, whereas ICSI is the process of selecting and injecting a single 
sperm into an oocyte. ICSI was originally developed to treat male factor infertility, however, its use 
has been greatly expanded in ART inclu ding insemination of cryopreserved oocytes, previous 
fertilization failure or poor fertilization results following IVF, unexplained infertility, in vitro maturation, 
cases of PGT when paternal contamination is of concern, and other clinically relevant indi cations at 
the physician's discretion (1). Selection of healthy sperm for use in ICSI is critical to ICSI success. 
Density gradient is a commonly used method to select sperm for ICSI, which depends on 
centrifugation , and is the standard of care for sperm p rocessing prior to ICSI in our institution . This 
technique requires mechanical and chemical processing that can increase oxygen free radical 
formation, which can cause sperm DNA damage and increase in DNA fragmentation (2, 3). Although 
conflicting data exi sts as to whether elevated levels of sperm DNA fragmentation compromises live 
birth rates in assisted reproductive technology (ART) treatments, some data has revealed that 
increased sperm DNA fragmentation decreases fertilization rates, decreases progressi on to good 
quality embryos, decreases pregnancy rates, and increases miscarriage rates (4 -10). Studies have 
shown elevated levels of sperm DNA fragmentation in infertile males with abnormal semen 
parameters (11 -13), however, interestingly data has revealed  that increase levels of DNA 
fragmentation can also be found in infertile males with normal semen parameters (14).  
 
Separation of sperm with microfluidics prior to ART resembles the physiologic environment that sperm 
encounters in the female reproductive t ract more closely compared to density gradient, and has been 
proposed to decrease sperm DNA fragmentation. Indeed, separation via ZyMot, a microfluidic 
technique has been shown to significantly decrease sperm DNA fragmentation compared to the 
traditional d ensity gradient technique (15). In a non -randomized study with a small sample size 
enrolling couples with recurrent ART failure and male factor infertility with high sperm 
defragmentation, outcomes with density gradient versus microfluidic sperm separation  using ZyMot 
were compared and revealed that embryo euploid rates following PGT -A and pregnancy rates were 
significantly improved with the use of ZyMot (16). A retrospective study evaluating pregnancy rates 
using ZyMot sperm separation compared to density gradient for intrauterine insemination (IUI) 
revealed significantly higher ongoing pregnancy rates with use of ZyMot compared to density gradient 
(17). Additionally, a prospective randomized study evaluating ZyMot sperm separation with the swim 
up techniqu e for patients undergoing ICSI due to unexplained infertility revealed a significant increase 
in good quality embryo formation with ZyMot sperm separation, however, this study included a 
significant proportion of embryos evaluated and transferred at day [ADDRESS_379391] of care (18).  
 
The aim of our study is to evaluate whether good quality embryo formation is significantly different 
following ICSI comparing sperm separated using ZyMot with density gradient.  
 
References  
Study: i21 -[ZIP_CODE]  
Page 9 of 25 
1. Practice Committees of the American Society for Reproductive M, the Society for Assisted 
Reproductive Technology. Electronic address aao. Intracytoplasmic sperm injection (ICSI) for 
non-male factor indications: a co mmittee opi[INVESTIGATOR_1649]. Fertility and S terility 2020 ;114:239 -45. 
2. Zalata A, Hafez T, Comhaire F. Evaluation of the role of reactive oxygen spec ies in male 
infertility. Human R eproduction 1995;10:1444 -51. 
3. Zini A, Finelli A, Phang D, Jarvi K. Influence of semen processing technique on human sperm 
DNA integrity . Urology 2000;56:1081 -4. 
4. Borini A, Tarozzi N, Bizzaro D, Bonu MA, Fava L, Flamigni C  et al.  Sperm DNA fragmentation: 
paternal effect on early post -implantation em bryo development in ART. Human R eproduction 
2006;21:[ADDRESS_379392] development after in vitro fertilizatio n. Fertility 
and S terility 2004;82:[ADDRESS_379393] of sperm 
DNA fragmentation on miscarriage rates: a systematic r eview and meta -analysis. Human 
Reproduction 2012;27:2908 -17. 
7. McQueen DB, Zhang J, Robins JC. Sperm DNA fragmentation and recurrent pregnancy loss: 
a systematic review an d meta -analysis. Fertility and S terility 2019;112:54 -60 e3.  
8. Borges E, Jr., Zanetti BF, Setti AS, Braga D, Provenza RR, Iaconelli A, Jr. Sperm DNA 
fragmentation is correlated with poor embryo development, lower implantation rate, and higher 
miscarr iage rate in reproductive cycles of non -male fac tor infertility. Fertility and S terility 
2019;112:[ADDRESS_379394] udy Team. Fertility and S terility 
2000;73:43 -50. 
10. Bungum M, Humaidan P, Axmon A, Spano M, Bungum L, Erenpreiss J  et al.  Sperm DNA 
integrity assessment in prediction of assisted reproduc tion technology outcome. Human 
Reproduction 2007;22:174 -9. 
11. Zini A, Biele cki R, Phang D, Zenzes MT. Correlations between two markers of sperm DNA 
integrity, DNA denaturation and DNA fragmentation, in fertile and infertile men. Fertility and 
Sterility 2001;75:[ADDRESS_379395] pregnancy rates. 
Fertility and S terility 2005;84:130 -40. 
13. Moskovtsev SI, Willis J, White J, Mullen JB. Sperm DNA damage: correlation to severity of 
semen abnormal ities. Urology 2009;74:[ADDRESS_379396], Nada EA, El -Tonsy MH, Alvarez JG  et al.  Increased sperm 
nuclear DNA damage in normozoospermic infertile men: a pr ospective study. Fertility and 
Sterility 2002;78:313 -8. 
15. Quinn MM, Jalalian L, Ri beiro S, Ona K, Demirci U, Cedars MI  et al.  Microfluidic sorting selects 
sperm for clinical use with reduced DNA damage compared to density gradient centrifugation 
with swim -up in split semen samples. Human R eproduction 2018;33:1388 -93. 
16. Parrella A, Keating  D, Cheung S, Xie P, Stewart JD, Rosenwaks Z  et al.  A treatment approach 
for couples with disrupted sperm DNA integrity and recurrent ART failure. Journal of assisted 
reproduction and genetics 2019;36:2057 -66. 
17. Gode F, Bodur T, Gunturkun F, Gurbuz AS, Tamer  B, Pala I  et al.  Comparison of microfluid 
sperm sorting chip and density gradient methods for use in intrauterine inse mination cycles. 
Fertility and S terility 2019;112:842 -8 e1.  
18. Yetkinel S, Kilicdag EB, Aytac PC, Haydardedeoglu B, Simsek E, Cok T. Effects  of the 
microfluidic chip technique in sperm selection for intracytoplasmic sperm injection for 
unexplained infertility: a prospective, randomized controlled trial. Journal of assisted 
reproduction and genetics 2019;36:403 -9. 
 
2.2.1 Device Preclinical Expe rience  
Study: i21 -[ZIP_CODE]  
Page 10 of 25 
The ZyMot Multi Sperm Separation Device (850μl) is used to prepare motile sperm for use in ART. 
ZyMot separates motile sperm from the semen based on the motility of the sperm within a 
microenvironment. The ZyMot Multi sperm separation device has an  inlet port for applying the semen 
sample to the lower sample chamber and an outlet port for collecting the motile sperm from the upper 
collection chamber. The chambers are separated by a microporous filter or membrane. After 
incubation at 37C for 30 min, the culture medium containing motile sperm is collected from the outlet 
port. 
 
The device is made from Polymethylmethacrylate, borosilicate glass, flash -spun high -density 
polyethylene fibers. The devices are gamma radiation -sterilized devices with a steril ity assurance 
level (SAL) of 10 -6. They are individually packaged and for single -use only.  
 
This device has been FDA approved for our proposed use (see attached).  
 
2.2.2 Device Clinical Experience  
Separation via ZyMot has been shown to significantly decrease sperm DNA fragmentation compared 
to the traditional density gradient technique (15). In a non -randomized study with a small sample size 
enrolling couples with recurrent ART failure and male factor infertility with high sperm 
defragme ntation, outcomes with density gradient versus microfluidic sperm separation using ZyMot 
were compared and revealed that embryo euploid rates following PGT -A and pregnancy rates were 
significantly improved with the use of ZyMot (16). A retrospective study evaluating pregnancy rates 
using ZyMot sperm separation compared to density gradient for intrauterine insemination (IUI) 
revealed significantly higher ongoing pregnancy rates with use of ZyMot compared to density gradient 
(17). Additionally, a prospective randomized study evaluating ZyMot sperm separation with the swim 
up technique for patients undergoing ICSI due to unexplained infertility revealed a significant increase 
in good quality embryo formation with ZyMot sperm separation, however, this study incl uded a 
significant proportion of embryos evaluated and transferred at day [ADDRESS_379397] of care (18).  
 
3 - Rationale/Significance  
3.[ADDRESS_379398] ART success rates. 
Sperm separation via microfluidics separates sperm in a more physiologic fashion and has been 
shown to decrease DNA fragmentation as compared to the density gradient.  
 
3.2 Purpose of Study/Potential Impact  
We intend to evaluate whether formation of high -quality embryos following ICSI are improved with 
ZyMot microfluidic sperm separation compared to density gradient. Potential impact of the study could 
be that good quality embryo formation is improved  with ZyMot compared with density gradient, which 
could have a positive impact on ART success rates.  
 
3.3.[ADDRESS_379399] to the quality of embryo formation with the 
use of the ZyMot device. Additionally, enrollment in the study can incur possible psychological distress 
due to study participation.  
 
Study: i21 -[ZIP_CODE]  
Page 11 of 25 
Procedures to limit psychological distress will be a thorough informed consent process, ability to 
discuss with any participating provider questions related to the study, and ability to withdraw 
enrollment at any point prior to insemination of the oocytes.  
 
3.3.2 Potential Benefits  
Potential benefit to study enrollment could be that good quality embryo formation is improved following 
sperm separation with ZyMot compared to density gradient, which could improve the participant's 
ART success rates.  
 
4 - Stud y Objectives  
4.1 Hypothesis  
We hypothesize that the percentage of good quality embryo formation following ICSI will be improved 
with sperm separated via ZyMot compared to density gradient.  
 
4.2 Primary Objective  
The primary objective of this study is to evaluate whether the percentage of good quality embryo 
formation following ICSI is improved with the use of ZyMot method of microfluidic sperm separation 
compared to density gradient.  
 
4.3 Secondary Objectives  
The primary objective of this study is to eva luate whether the percentage of good quality embryo 
formation following ICSI is improved with the use of ZyMot method of microfluidic sperm separation 
compared to density gradient.  
 
The secondary objectives will be to evaluate:  
1. Sperm parameters prior to an d following sperm separation with ZyMot compared to density 
gradient  
2. Normal  fertilization rates following ICSI comparing sperm separation with ZyMot with density 
gradient  
3. Euploid rates, in the event that PGT -A was performed, following ICSI comparing sperm 
separation with ZyMot with density gradient  
4. Embryo transfer results including:  
a. Not pregnant  
b. Biochemical pregnancy, defined as BHCG value > 5 mIU/ml without ultrasound 
evidence of gestational sac within the uterus  
c. Clinical miscarriage, defined as loss of a pregnancy following a positive BHCG value 
and ultrasound revealing presence of a gestational sac within the uterus  
d. Clinical pregnancy, defined as positive BHCG with a gestational sac within the uterus  
e. Ongoing Pregnancy, defined as a positive BHCG value wit h ultrasound evidence of 
intrauterine gestational sac at or past [ADDRESS_379400] of care, patients will be contact[CONTACT_309451]. Pregnancy outcomes will be recorded in the 
patient’s medical record.   
 
5 - Study Design  
5.1 General Design Description  
Study: i21 -[ZIP_CODE]  
Page 12 of 25 
This study will be a randomized sister oocyte (oocytes from the same patient within the same cycle) 
study at a single academic institution. By [CONTACT_309452] , we will eliminate any potential 
confounding variables.  
 
5.1.[ADDRESS_379401] stage embryos on day 5 or day 6 of culture with 
an ov erall quality grade of good or fair.  
 
5.2.2 Secondary and Exploratory Outcome Variable s 
The secondary outcomes will be to evaluate:  
1. Sperm parameters prior and following sperm separation with ZyMot compared to density 
gradient.  
2. Sperm parameters that will be evaluated are sperm concentration, percent motility, and grade 
of forward progression.  
3. Normal fertilization rates following ICSI comparing sperm separation with ZyMot to density 
gradient. Normal fertilization will be defined as visualization of exa ctly two pronuclei between 
16-[ADDRESS_379402] -insemination.  
4. Euploid, aneuploid, and mosaic rates in the event that PGT -A was performed following ICSI 
comparing sperm separation with ZyMot to density gradient. PGT -A biopsy samples will be 
sent to and analyzed  by [CONTACT_309453].  
5. Euploid embryo will be defined as 46XX or 46XY. Mosaic rates will be defined as presence of 
euploid and aneuploid cells and be reported as high or low mosaic. High mosaicism will be 
defined as embryos having 41 - 80% aneuploid cells, w hereas, low mosaicism will be defined 
as 20 - 40% aneuploid cells.  
6. Embryo transfer results including:  
a. Not pregnant  
b. Biochemical pregnancy, defined as BHCG value > 5 mIU/ml without ultrasound 
evidence of gestational sac within the uterus  
c. Clinical miscarriage, defined as loss of a pregnancy following a positive BHCG value 
and ultrasound revealing presence of a gestational sac within the uterus  
d. Clinical pregnancy, defined as positive BHCG with a gestational sac within the uterus  
e. Ongoing Pregnancy, de fined as a positive BHCG value with ultrasound evidence of 
intrauterine gestational sac at or past [ADDRESS_379403], or definite movement of 
the voluntary muscles.  
g. Ectopic Pregnancy, defined as positive BHCG and presence of pregnancy outside of 
the uterus.  
 
5.3 Study Population  
Study: i21 -[ZIP_CODE]  
Page 13 of 25 
The study population will include all patient/sperm source dyads over [ADDRESS_379404] a significant difference in our primary outcome. If 6 oocytes are 
obtained from each patient enrolled in the study, then 68 patient/sperm source dyads will be enrolled.  
 
Based on our 2020 data, there was a total of 1,680 mature oocytes from 137 retrievals that produced 
6 or more mature oocytes for ICSI insemination, from 12 1 different patients. The average number of 
mature oocytes within ICSI cycles with 6 or more mature oocytes obtained was 12 mature oocytes. 
Based on this data, we anticipate 138 patient cycles are needed for this study and this could include 
up to 138 patient/sperm source  dyads . 
  
5.3.2 Eligibility Criteria/Vulnerable Populations  
Eligibility will be determined by [CONTACT_35425], nurse practitioner, or research assistant involved 
in the care of the subject.  
 
Inclusion criteria for patients will include:  
1. Patient(s) over 18 years of age  
2. Patient(s) capable of providing informed consent  
3. Use or possible use of ICSI for oocyte insemination  
4. At least 6 mature oocytes at time of insemination via ICSI  
 
Exclusion criteria for patients:  
1. Patient under 18 y/o  
2. Patients not capable of providing informed consent  
3. Use of IVF for insemination  
4. Less than 6 mature oocytes at time of retrieval   
5. Anonymous donor sperm source  
6. Surgically retrieved sperm  
7. Sperm sample not sufficient for use with ZyMot device  
 
Inclusion criteri a for donors:  
1. Donor(s) over 18 years of age  
2. Donor(s) capable of providing informed consent  
3. Use of ejaculate sperm, fresh or frozen, for insemination  
4. Sufficient sperm for use of ZyMot  
 
Exclusion criteria for donors:  
1. Anonymous donors  
 
This study will not enroll vulnerable subjects ; however, we routinely  follow patients through their 
pregnancy to determine the outcome of embryo -transfer and will use the data from their standard of 
care follow -up calls for this study. The follow -up is considered minimal risk  as it only involves data 
collection. No inducements, monetary or otherwise, will be offered to terminate a pregnancy. 
Individuals engaged in the research will have no part in any decisions as to the timing, method, or 
procedures used to terminate a pregna ncy. Individuals engaged in the research will have no part in 
determining the viability of a neonate.  
 
6 - Methods  
6.1 Treatment – Device  
Study: i21 -[ZIP_CODE]  
Page 14 of 25 
 
6.1.1 Intended use for the device  
The intended use for the ZyMot device is to separate sperm prior to ICSI inseminati on alongside and 
comparing it to sperm separation with use of density gradient.  
 
6.1.2 Device administration and schedule  
Patient/sperm source  dyads  enrolled in the study and meeting inclusion criteria will have their sperm 
sample prepared prior to, or n ear the time of, oocyte retrieval. Semen parameters will be recorded 
prior to separation. Semen will be split and separated via ZyMot and density gradient.  
 
Density gradient will be performed as follows:  
• Density gradient centrifugation will be performed us ing a one -layer preparation of 90% Isolate 
(Irvine Scientific) in 15 mL conical tubes. Semen will be layered over 1 mL of gradient and 
then centrifuged for 15 min at 300xg. The supernatant will be removed and discarded. The 
sperm pellet will be washed by m ixing with Multipurpose Handling Medium Complete (Irvine 
Scientific) and centrifuging the sample for 5 min at 400xg. After the wash, the supernatant is 
removed and discarded and the pellet is re -suspended in culture medium (Continuous Single 
Culture -NX Com plete, Irvine Scientific), assessed for sperm parameters, and held at room 
temperature until insemination.  
 
ZyMot separation using the Multi (850 uL) microfluidic separation device will be performed as 
follows:  
• 850 uL of untreated semen will be directly deposited into the inlet port of the ZyMotTM Multi 
device, followed by [CONTACT_7581] 750 uL culture medium (Continuous Single Culture - NX 
complete, Irvine Scientific) in the outlet port and throughout the upper collection chamber. The 
device will t hen be incubated in a humidified 37C CO2 incubator for [ADDRESS_379405] motile sperm will swim through the microporous filter and 
into the upper collection chamber, where they will be recovered via the outlet port. 500  uL of 
the sperm sample will be removed and placed in a separate tube for analysis and 
insemination.  
• After sperm processing, sperm parameters will be evaluated and recorded for each 
preparation, including sperm concentration, percent motility, and grade of  forward 
progression. The density gradient preparation results will be recorded as Sample [ADDRESS_379406] (eMR) system gamete sheet. The ZyMot preparation results will be 
recorded as Sample 2 in the eMR system gamete sheet.  
• Mode of oocyt e insemination is ordered by [CONTACT_309454]’s chart. In the 
event that ICSI is ordered, the oocytes will be inseminated via ICSI. In the event that the 
physician orders ICSI per embryologist, the decision to perform ICSI will be a c linical decision 
based on the final prepared semen sample and/or other relevant clinical data. The sample 
must meet the f ollowing minimal criteria below in order to be eligible for IVF:  
 
 
 
 
 
 
 
 
• In the event that any of the parameters above are not met and/or other clinical parameters 
favoring ICSI insemination over IVF including, but not limited to, microscopic appearance of 
the oocytes, review of previous insemination cycles, and previous morpho logy grading of 
sperm, ICSI will be performed.  
• In the event that the parameters above are met and there are not any other factors favoring 
ICSI insemination, the oocytes will be inseminated via IVF from sperm separated by [CONTACT_309455]  ≥ 1.0 mL  ≥ 0.25 mL  
Concentration  ≥ 15 mil/mL  NA 
Motility  ≥ 35%  ≥ 70%  
Forward 
Progression   
≥ 2  
≥ 3 
Study: i21 -[ADDRESS_379407] sperm parameters following ZyMot separated sperm 
and density gradient separated sperm will be recorded as per our secondary objectives.   
• As per our standard verbal and written consenting protocols, patients are aware that their 
oocytes may undergo ICSI the day of oocyte retrieval based on above criteria. The decision 
to perform ICSI will not be affected in any way by [CONTACT_107890].  
• Following oocyte retrieval, oocytes will be denuded of their cumulus cells per standard 
protocol . If at least 6 mature oocytes (determined by [CONTACT_309456] a polar body) are present, 
half the oocytes will be ICSI inseminated with sperm prepared v ia ZyMot device and half will 
be ICSI inseminated with sperm prepared with density gradient. Patients whose patient 
identification number (PID) is even will have the group of oocytes inseminated with sperm 
separated via ZyMot device recorded first in the e MR gamete sheet (beginning with oocyte 
#1.) Patients with an odd PID will have the oocytes inseminated with sperm separated via 
density gradient recorded first in the eMR gamete sheet (beginning with oocyte #1.) In the 
event of an odd number of oocytes, th e patients with even PI[INVESTIGATOR_309442]. Inseminated oocytes will 
be grouped into sep arate wells of a LifeGlobal 4 well GPS dish (Cooper Surgical) by [CONTACT_309457] — one well will contain all oocytes inseminated with sperm selected by 
[CONTACT_309458] a separate well will contain all oocytes inseminated with sperm selected by  
[CONTACT_309459].  
 
Control Group of Oocytes:  
Half of the eggs will be inseminated via ICSI using sperm selected by [CONTACT_309460].  
 
Treatment Group of Oocytes:  
• Half of the eggs will be inseminated via ICSI using sperm selected using ZyMot.  
• Fertilization assessment will be performed between 16 and 18 hours after insemination and 
normal fertilization will be considered visualization of exactly two pronuclei. Normally fertilized 
oocytes (embryos) will then be cultured in C ontinuous Single Culture Medium — NX Complete 
(Irvine Scientific) in separate, numbered droplets in LifeGlobal microdrop GPS dishes (Cooper 
Surgical.) The numbers of the droplets will correlate to oocyte/embryo number in the eMR 
gamete sheet and, thereby, also correlate to the type of sperm used for the insemination. 
Development of the embryos will be assessed on culture days 5 and 6 and embryo stage and 
grade will be recorded for each embryo.  
• Decision as to which embryo to transfer will be made by [CONTACT_309461]. Transfer of embryo is generally based on ploidy status 
(if PGT -A was performed) or blastocyst grade (if PGT -A was not performed). In the event that 
two embryos of similar quality are ava ilable for transfer, priority is given to lowest embryo 
number (correlated to oocyte/embryo number ). The decision as to which embryo to transfer 
will be made regardless of whether the s perm used to inseminate the oocyte was processed 
with density gradient or ZyMot and will be as per our standard protocol.  
 
6.1.3 Method of Assignment/Randomization  
Patient/sperm source  dyads  meeting inclusion criteria and enrolled in the study will have their sperm 
sample prepared prior to or near the time of oocyte retriev al. Semen parameters will be recorded prior 
to separation. Semen will be split and separated via ZyMot and density gradient.  
 
Following oocyte retrieval, oocytes will be denuded of their cumulus cells per standard protocol . If at 
least 6 mature oocytes (de termined by [CONTACT_309456] a polar body) are present, half the oocytes will 
Study: i21 -[ZIP_CODE]  
Page 16 of 25 
be ICSI inseminated with sperm separated via ZyMot device and half will be ICSI inseminated with 
sperm prepared with density gradient. Patients whose patient identification numbe r (PID) is even will 
have the group of oocytes inseminated with sperm separated via ZyMot device recorded first in the 
eMR gamete sheet (beginning with oocyte #1.) Patients with an odd PID will have the oocytes 
inseminated with sperm separated via density gradient recorded first in the eMR gamete sheet 
(beginning with oocyte #1.) In the event of an odd number of oocytes, the patients with even PI[INVESTIGATOR_309443] h ave the extra oocyte inseminated with sperm separated via density gradient.  
 
6.1.4 Device Calibration  
No calibration of the device is required. Each device is single use and disposable after use.  
 
6.1.5 Storage Condition  
The device will be stored at room temperature within our embryology laboratory as per manufacturer 
protocol . Receipt of the device, including number of devices received, lot number(s) of the devices, 
open and close dates for each lot, and certificates of analysis for each lot will be recorded and/or filed. 
Unused devices at the conclusion of the study will be returned to the study sponsor.  
 
6.1.6 Concomitant  therapy  
None  
 
6.1.7 Restrictions  
Restrictions for use of the device will include severe male factor defined as an initial eja culate sample 
with <0.5 million total motile sperm and/or no sperm observed with progressive forward motility 
(forward progression grade of 2.) Any surgically derived sperm will be excluded from the study. 
Additionally, when orders are written for ICSI per  embryologist, any specimen not meeting above 
criteria for ICSI (see section 6.1.2), will be inseminated via IVF and therefore, their oocytes will not be 
inseminated with ZyMot separated sperm.  
 
6.2 Assessments  
 
6.2.1 Efficacy  
The efficacy of the device w ill be evaluated by [CONTACT_309462], percentage of good quality 
embryos available following ICSI insemination with ZyMot separated sperm compared to insemination 
with density gradient separated sperm.  
 
6.2.2 Safety/Pregnancy -related policy  
Not Appli cable.  
 
[IP_ADDRESS] Adverse Events Definition and Reporting  
Definitions  
Unanticipated Problems Involving Risk to Subjects or Others Any incident, experience, or outcome 
that meets all of the following criteria: Unexpected in nature, severity, or frequency (i. e. not described 
in study -related documents such as the IRB -approved protocol or consent form, the investigators 
brochure, etc.)  
 
Related or possibly related to participation in the research (i.e. possibly related means there is a 
reasonable possibility that the incident experience, or outcome may have been caused by [CONTACT_9156])  
 
Suggests that the research places subjects or others at greater risk of harm (including physical, 
psychological, economic, or social harm ). 
 
Adverse Event  
Study: i21 -[ZIP_CODE]  
Page 17 of 25 
An adverse event  (AE) is any symptom, sign, illness or experience that develops or worsens in 
severity during the course of the study. Intercurrent illnesses or injuries should be regarded as 
adverse events. Abnormal results of diagnostic  procedures are considered adverse events if the 
abnormality:  
• results in study withdrawal  
• is associated with a serious adverse event  
• is associated with clinical signs or symptoms  
• leads to additional treatment or to further diagnostic tests  
• is considered by  [CONTACT_15369] -serious. A serious adverse event  is any AE 
that is:  
• fatal 
• life-threatening  
• requires or prolongs hospi[INVESTIGATOR_4408]  
• results in persistent or s ignificant disability or incapacity  
• a congenital anomaly or birth defect  
• an important medical event  
• Important medical events are those that may not be immediately life threatening, but are 
clearly of major clinical significance. They may jeopardize the sub ject, and may require 
intervention to prevent one of the other serious outcomes noted above. For example, drug 
overdose or abuse, a seizure that did not result in in -patient hospi[INVESTIGATOR_309444].  
 
All adverse events that do not meet any of the criteria for serious should be regarded as non-serious 
adverse events . 
 
Preexisting Condition  
A preexisting condition is one that is present at the start of the study. A preexisting condition should 
be recorded as an adverse event if the frequency, intensity, or the character of the condition worsens 
during the study period.  
 
General Physical Examination Findings  
At screening, any clinically significant abnormalit y should be recorded as a preexisting condition. At 
the end of the study, any new clinically significant findings/abnormalities that meet the definition of an 
adverse event must also be recorded and documented as an adverse event.  
 
Post -study Adverse Event  
All unresolved adverse events should be followed by [CONTACT_1374], 
the subject is lost to follow -up, or the adverse event is otherwise explained. At the last scheduled visit, 
the investigator should instruct each subject t o report any subsequent event(s) that the subject, or the 
subject's personal physician, believes might reasonably be related to participation in this study. The 
investigator should notify the study sponsor of any death or adverse event occurring at any tim e after 
a subject has discontinued or terminated study participation that may reasonably be related to this 
study. The sponsor should also be notified if the investigator should become aware of the 
development of cancer or of a congenital anomaly in a subs equently conceived offspring of a subject 
that has participated in this study.  
 
 Recording of Adverse Events  
At each contact [CONTACT_1155], the investigator must seek information on adverse events by [CONTACT_28812], as appropriate, by [CONTACT_309463]. Information on all adverse events should be 
recorded immediately in the source document, and also in the appropriate adverse event module of 
Study: i21 -[ADDRESS_379408] be followed up to determine the final outcome. Any serious adverse event that 
occurs after the study p eriod and is considered to be possibly related to study participation should be 
recorded and reported immediately.  
 
Reporting of Serious Adverse Events and Unanticipated Problems  
 
For Narrative Reports of Safety Events  
 
If the report is supplied as a narra tive, the minimum necessary information to be provided at the time 
of the initial report includes:  
• Study identifier  
• Study Center  
• Subject number  
• A description of the event  
• Date of onset  • Current status  
• Whether study treatment was discontinue d 
• The reason why the event is classified as serious  
• Investigator assessment of the association between 
the event and study treatment  
  
Investigator reporting: notifying the IRB Federal regulations require timely reporting by [CONTACT_309464]. The following describes 
the NYULMC IRB reporting requirements, though Investigators at participating sites are responsible 
for meeting the specific requirements of their IRB of record.  
 
Report prom ptly, but no later than 5 working days:  
Researchers are required to submit reports of the following problems promptly but no later than 5 
working days from the time the investigator becomes aware of the event:  
 
Unanticipated problems including adverse even ts that are unexpected and related  
Unexpected : An event is "unexpected" when its specificity and severity are not accurately reflected 
in the protocol -related documents, such as the IRB -approved research protocol, any applicable 
investigator brochure, and the current IRB -approved informed consent docu ment and other relevant 
sources of information, such as product labeling and package inserts.  
 
Related to the research procedures : An event is related to the research procedures if in the opi[INVESTIGATOR_118637], the event was more  likely than not to be caused by [CONTACT_118689].  
 
Harmful : either caused harm to subjects or others, or placed them at increased risk  
 
Other Reportable events: The following events also require prompt reporting to the IRB, though no 
later than 5 working days : 
 
Complaint of a research subject  when the complaint indicates unexpected risks or the complaint 
cannot be resolved by [CONTACT_5051].  
 
Protocol deviation s or violations  (includes intentional and accidental/unintentional deviations from 
the IRB approved protocol) for any of the following situations:  
one or more participants were placed at increased risk of harm  
the event has the potential to occur again  
the deviation was necessary to protect a subject from immediate harm  
Study: i21 -[ZIP_CODE]  
Page 19 of 25 
Breach of confidentiality  
 
New Information indicating a change to the risks or potential benefits of the research, in terms of 
severity or frequency. (e.g. analysis indicates lower -than-expe cted response rate or a more severe or 
frequent side effect; FDA labeling change or withdrawal from market)  
 
Reporting Process  
The reportable events noted above will be reported to the IRB using a Reportable New Information 
submission and will include a de scription of the event with information regarding its fulfillment of the 
above criteria, follow -up/resolution, and need for revision to consent form and/or other study 
documentation. Copi[INVESTIGATOR_309445] w ill be kept 
in the Clinical Investigator's study file.  
 
6.3.[ADDRESS_379409] time devoted to this study will be the reviewing and signing the informed consent.  
 
The timepoints for involvement in the study will be:  
1. The process of informed consent for patient/sperm source dyads  
2. The oocyte retrieval - After retrieval in the event that there are [ADDRESS_379410], if the patient does not meet 
criteria for IVF the day of oocyte retrieval (as per section 6.3), the oocytes will be inseminated 
via IVF with density separated sperm only, however, the pre and post sperm parameters  
following ZyMot separated sperm and density gradient separated sperm will be recorded as 
per our secondary objectives. Similarly, in the event that there are less than [ADDRESS_379411] of care, patients will be contact[CONTACT_309465] t heir pregnancy outcome. Pregnancy outcomes will be recorded in the 
patient’s medical record.   
 
Study: i21 -[ZIP_CODE]  
Page 20 of 25 
6.3.2 Informed Consent  
Consent  and other informational documents provided to participants consent forms describing in 
detail the study agent, study procedures, and risks are given to the participant and written 
documentation of informed consent is required prior to starting intervention/administering study 
product.  
 
Consent procedures and documentation informed consent is a process that is initiated prior to the 
individual's agreeing to participate in the study and continues throughout the individual's study 
participation. Extensive discussion of risks and possible benefits of participation will be provided to 
the participants. Consent forms will be IRB -approved a nd the participant will be asked to read and 
review the document. All discussions about this research with patient/sperm source  dyads  will occur 
in private consultation offices, exam rooms, or a secure WebEx  platform.  The patient/sperm source 
dyad will have the consent emailed to the patient /sperm source dyad to  be signed during the WebEx  
meeting  or in person . The study investigator and or research assistant will explain the study protocol 
and details of the patient/sp erm source ’s role and anticipated experience during the procedure, 
allowing the patient/sperm source s to ask questions, which will be answered to the subject's 
satisfaction. The consenter will also ask questions of the prospective patient/sperm source s to assess 
that they have understood the information presented to them. The participants should have the 
opportunity to discuss the study with their relatives or think about it prior to agreeing to participate. 
The patient/sperm source s will sign the informed consent document prior to any procedures being 
done specifically for the study.  The investigator or research assistant who obtained consent will sign 
the consent form. A signed copy of the consent form will be provided to the patient/sperm source 
dyad.  The day of the oocyte retrieval, the sperm will be processed as explained above and used to 
inseminate the occytes with both sperm processed using the density gradient and ZyMot microfluidics 
as long as they are eligible for inclusion. Subjects can withdraw f rom the study at any time if they no 
longer wish their data to be collected  and used for study purposes . However, they will be informed 
that if they withdraw after insemination,  the insemination process cannot be reversed . The rights and 
welfare of the par ticipants will be protected by [CONTACT_309466].  
 
If, during this interview, it becomes apparent that the prospective patient  / sperm sour ce dyad  lacks 
sufficient knowledge and comprehension of the information represented by [CONTACT_309467], they will be excluded from pa rticipating in the study.  
 
A copy of signed informed consent document will be obtained and stored in a binder locked in the 
investigators ’ office. The consent process, including the name [CONTACT_21811], will 
be thoroughly documented in  the patient/sperm source  dyad’s  research record. Any alteration to the 
standard consent process ( e.g., use of a translator, consent document presented orally, etc.) and the 
justification for such alteration will likewise be documented.  
 
See attached infor med consent.  
 
6.3.3 Screening  
All patients /donor dyads  potentially undergoing ICSI and meeting inclusion criteria for the study will 
be approached to participate in the study. Screening will be performed  by [CONTACT_309468] S pecialists of NY.  
 
6.3.4 Recruitment, Enrollment and Retention  
Recruitment into the study will be performed by a study investigator at NYU Langone RSO FNY. 
Patient/sperm source dyads are recruited from the study investigators’ practice (RSOFNY) during a 
routine clinical visit. If patient/sperm source  dyads  desire to enroll in the study, it will be denoted in 
their medical record chart. If they meet eligibilit y criteria on the day of oocyte retrieval (no evidence of 
severe male factor infertility or surgically derived sperm, at least 6 mature oocytes available for 
randomization, and possibility for ICSI insemination) the study will be performed as per study pro tocol.  
Study: i21 -[ZIP_CODE]  
Page 21 of 25 
 
In the event that the patient consented to the study but the provided semen sample on the day of 
oocyte retrieval shows severe male factor infertility. The patient/sperm source dyad will then be 
withdrawn from the study since the sample will not qu alify for preparation via ZyMot nor density 
gradient.  
 
In the event that the patient/sperm source dyad consented to the study but does not meet the inclusion 
criteria of ICSI insemination or at least 6 mature oocytes available for insemination, inseminatio n will 
occur only with the sperm separated via density gradient, however, the sperm parameters following 
ZyMot and density gradient sperm separation will be recorded. The data on sperm parameters after 
sperm separation via ZyMot and density gradient will s till be collected but the patient/sperm source 
dyad will have no further participation in the study.  
 
6.3.5 On Study Visits  
Not applicable.  
 
6.3.6 End of Study and Follow -up 
If the patient/ donor dyad is enrolled into the study, the primary and secondary da ta endpoints will be 
documented as they become available.  
 
No further follow up for those subjects withdrawn from the study will be needed as they will undergo 
ART procedures as per our standard of care.  
 
6.3.7 Removal of subjects  
Following enrollment i nto the study, the patient/sperm source dyads may withdraw from the study at 
any point prior to insemination of the oocytes.  
 
In the event that the patient/sperm source dyad consented to the study but the provided semen 
sample on the day of oocyte retrieva l shows severe male factor infertility as per above criteria, the 
patient/sperm source dyad will be withdrawn from the study since the sample will not qualify for 
preparation via ZyMot nor density gradient.  
 
In the event that the patient/sperm source dyad consented to the study but does not meet the inclusion 
criteria of ICSI insemination or at least 6 mature oocytes available for insemination, insemination will 
occur only with the sperm separated via density gradient, however, the sperm parameters followin g 
ZyMot and density gradient sperm separation will be recorded. The data on sperm parameters after 
sperm separation via ZyMot and density gradient will still be collected but the patient/sperm source 
dyad will have no further participation in the study.  
 
6.4 Statistical Method  
6.4.1 Statistical Design  
All data will be de -identified and then will be analyzed by a statistician. Descriptive statistics of the 
study sample will be calculated (mean ± standard deviation or median [25th, 75th percentiles] for 
continuous variables; frequency and percent for categorical data. Paired analyses will be performed. 
A result will be considered statistically significant at the p<0.05 level of significance. All analyses will 
be performed using SAS versi on 9.4 (SAS Institute Inc., Cary, NC).  
 
6.4.2 Sample Size Considerations  
For a two -tailed McNemar’s test with alpha level 0.05, the following relation yields an approximate 
power of 80% to detect a difference d between proportions p 1 and p 2:n = 16pq (1 - r)/d2 where n is 
the size of the sample (i.e. number of eggs), p = (p 1 + p 2)/2, q= 1 - p, d = |p 2 - p1|, and r is the phi 
Study: i21 -[ZIP_CODE]  
Page 22 of 25 
correlation coefficient1.We will assume a conservative estimate for the  correlation r=0 .5. Assuming a 
48% good quality blastocyst development rate and a 7% improvement in good quality blastocyst 
development with ZyMoT, we would need a total of 408 oocytes randomized to either density gradient 
or ZyMoT separation, which would equate to 68 patient /sperm source dyads each with ≥6 eggs 
retrieved.  
 
6.4.3 Planned Analyses  
[IP_ADDRESS] Primary Analyses  
Percentage of good quality embryo formation between control and experimental arm will be analyzed 
using McNemar’s test.  
 
[IP_ADDRESS] Secondary Objectives Analyse s  
Sperm parameters following ZyMot and density gradient sperm separation, as well as Euploid rates 
in the event that PGT -A was performed following ICSI comparing sperm separation with ZyMot to 
density gradient, will be assessed using the paired t -test, Wilcoxon signed rank test , ora generalized 
linear mixed model (GLMM). A random subject -specific intercept and an unstructured correlation 
structure will be used to account for within -subject correlation between rates between the two groups. 
Data will be repo rted as least squares means with corresponding 95% confidence intervals.  
 
Pregnancy outcomes will be assessed using McNemar’s test. The difference in good quality 
blastocyst development rate and pregnancy outcomes between the ZyMot and density gradient 
separation groups will also be analyzed separately using a conditional logistic regression model with 
generalized estimating equations to account for both correlation between observations from the same 
patient and the size of the cohort of eggs from each pati ent. 
 
[IP_ADDRESS] Safety/Pregnancy -related policy  
Not applicable.  
 
[IP_ADDRESS] Analysis of Subject Characteristics  
Subject characteristics will be documented including female age, male age, infertility diagnosis, 
stimulation protocol, medications used, gonadotropi n dosage, method of trigger, infertility diagnosis, 
sperm parameters prior to sperm separation, gravity, parity, and previous pregnancy outcomes.  
 
[IP_ADDRESS] Interim Analysis  
An interim analysis will be performed  at the midway point of oocyte recruitment. In terim analysis will 
evaluate percentage of good quality embryo formation. Study will be terminated in the event that there 
is a significant decrease in good quality embryo formation in the study  arm compared to the control  
arm. 
 
[IP_ADDRESS] Health economic eva luation  
Not applicable.  
 
[IP_ADDRESS] Other  
Not applicable.  
 
6.4.4 Subsets and Covariates  
This study will be randomizing sister oocytes (oocytes from the same patient within the same cycle) 
and thus limiting the impact of confounding variables.  
 
6.4.5 Handling of Missing Data  
 
 
1 Lehr, R. G. 2001. Some practical considerations and a crude formula for estimating sample size for McNemar's 
test. Drug Information Journal, 35: 1227 –1233.  
Study: i21 -[ZIP_CODE]  
Page 23 of 25 
Missing data will be maintained as missing in the analysis datasets, unless specified otherwise. If it is 
deemed that imputing data is necessary, the analysis dataset will contain a new variable with the 
imputed value and th e original variable value will be maintained as missing.  
 
7 - Trial Administration  
7.1 Ethical Considerations: Informed Consent  and HIPAA Authorization  
The study will be conducted in accordance with the ethical principles that have their origin in the 
Declaration of Helsinki. Informed consents will be scanned into the patient's chart and hard copy will 
be stored in a locked file draw/cabinet at NYU Langone RSO FNY. The PI [INVESTIGATOR_9814] -investigators will 
have access to the locked storage unit.  
 
Data will be stor ed using codes assigned by [CONTACT_309469]. The data will 
be collected and stored on REDCap. Only investigators will have access to the samples and data.  
 
There is not any foreseeable possibility that a previously unknown conditio n (disease, genetic 
disposition, etc.) will be discovered as the result of the study procedure.  
 
Additional information as a result of this study will be added to the patient's medical record and include 
the use of ZyMot to process the sperm specimen and p ost-processing sperm parameters.  
 
7.[ADDRESS_379412] (IRB) Review  
The protocol, informed consent form(s), recruitment materials, and all participant materials will be 
submitted to the IRB for review and approval. Approval of both the protocol and the consent form will 
be obtained prior to enrolling any participants. Any amendment to the protocol will require review and 
approval by [CONTACT_3484]. All changes to the consent 
form will be IRB appro ved. 
 
7.[ADDRESS_379413] Confidentiality  
All data will be stored and analyzed in accordance with NYU's policy on retention of and access to 
research data. Potential identifiable information (patient and cycle ID) will be recorded as a numerical 
number. All research data will be maintained in tangible form and will be retained by [CONTACT_1961] [INVESTIGATOR_309446]'s Medical Cente r Information 
Technology (MCIT) department. The data will be stored for [ADDRESS_379414] access to the cabinet.  
 
7.4 Deviations/Unanticipated Problems  
Protocol d eviations are any noncompliance with the clinical trial protocol. The deviation may be either 
on the part of the participant, the investigator, or the study site staff.  
 
It will be the responsibility of the principal  investigator [INVESTIGATOR_309447]. All protocol deviations 
will be addressed in study source documents, and reported to the sponsor and to the local IRB per 
the guidelines.  
 
7.[ADDRESS_379415] will be available in the electronic 
Study: i21 -[ADDRESS_379416] datasheet.  
 
All data will be stored and analyzed in accordance with NYU's policy on retention of and access to 
research data. Potential identifiable information (patient and cycle ID) will be recorded as a numerical 
number. All research data will be maintained in tangible form and will be retain ed by [CONTACT_978] [INVESTIGATOR_309448]'s Medical Center Information Technology (MCIT) department. 
The data will be stored for [ADDRESS_379417] access to the cabinet.  
 
7.6 Data Quality Assurance  
The study investigators will be responsible for implementing and maintaining quality assurance and 
quality con trol systems to ensure that the trial is conducted and data are generated, documented 
(recorded), and reported in compliance with the protocol, GCP, and the applicable regulatory 
requirement(s).  
 
The study investigators will be responsible for securing agr eement from all involved parties to ensure 
direct access to all trial -related sites, source data/documents, and reports for the purpose of 
monitoring and auditing by [CONTACT_456], and inspection by [CONTACT_119121].  
 
Quality contr ol will be applied to each stage of data handling to ensure that all data are reliable and 
have been processed correctly.  
 
Agreements, made by [CONTACT_309470]/institution and any other parties involved with 
the clinical trial, will be in writing, as part of the protocol or in a separate agreement.  
 
7.7 Study Records  
Study records will include patient consents, protocols, electronic medical records, and data related to 
the study.  
 
7.8 Access to Source  
Access to study records will be limited to IRB -approved members of the study team. All data will be 
stored and analyzed in accordance with NYU's policy on retention of and access to research data. 
Potential identifiable information (patient and cycle ID) will be recorded as a numerical n umber. All 
research data will be maintained in tangible form and will be retained by [CONTACT_978] [INVESTIGATOR_309449]'s Medical Center Informa tion Technology (MCIT) department. The 
investigator will permit study -related monitoring, audits, and inspections by [CONTACT_1201]/EC, the sponsor, 
government regulatory bodies, and university compliance and quality assurance groups of all study 
related document s (e.g., source documents, regulatory documents, data collection instruments, study 
data etc.). Data may be shared with the sponsor of the study ; however, data will be de -identified prior 
to sharing the data.  
 
7.9 Data or Specimen Storage/Security  
All dat a will be stored and analyzed in accordance with NYU's policy on retention of and access to 
research data. Potential identifiable information (patient and cycle ID) will be recorded as a numerical 
number. All research data will be maintained in tangible fo rm and will be retained by [CONTACT_978] [INVESTIGATOR_309448]'s Medical Center Information Technology (MCIT) department. 
Study: i21 -[ADDRESS_379418] access to  the cabinet.  
 
7.10 Retention of Records  
All data will be kept for 6 years following completion of the study. If permission is needed to move or 
destroy the records, it will be the PI's responsibility.  
 
7.[ADDRESS_379419] through recruitment of sample size, preliminary results will be analyzed by [CONTACT_119785]  [INVESTIGATOR_6254]-investigator s. If the primary endpoint is adversely affected  by [CONTACT_30157], the study 
will be terminated. The primary endpoint will be percentage of good quality embryos comparing those 
inseminated with density processed sperm and ZyMot processed sperm. In the event that there is a 
statistically significant (p<0.05)  percentage of higher quality embryo formation in the embryos created 
via sperm inseminated with density processed sperm compared to ZyMot processed sperm, the study 
will be terminated. Preliminary analysis of the results will be communicated promptly to t he IRB.  
 
7.[ADDRESS_379420] with this study (patent ownership, royalties, or financial 
gain great er than the minimum allowable by [CONTACT_1385], etc.) will have the conflict reviewed by 
[CONTACT_33913] (CIMU) with a Committee -sanctioned conflict 
management plan that has been reviewed and approved by [CONTACT_1758] s ponsor prior to participation in 
this study. All NYULMC investigators will follow the applicable conflict of interest policies.  
 
7.17 Funding Source  
The study will be funded by [CONTACT_309471], manufacturer of the ZyMot device.  
 
7.18 Publication Plan  
Publication  procedures and authorship will be addressed in the Clinical Trials Agreement for this 
study.  